natgillin/translations-raw huggingface dataset:
Due to the risk of QTc prolongation associated with DM-6705, if co-administration of delamanid with ritonavir is considered necessary, very frequent ECG monitoring throughout the full delamanid treatment period is recommended (see section 4.4 and refer to the delamanid Summary of Product Characteristics)
Zbog rizika od produženja QTc intervala povezanog s metabolitom DM-6705, ukoliko je nužna istodobna primjena delamanida i ritonavira, preporučuje se učestalo praćenje EKG-a bolesnika tijekom cijelog razdoblja liječenja delamanidom (vidjeti dio 4.4 i Sažetak opisa svojstava lijeka za delamanid).
Concomitant use of ritonavir (400 mg twice daily and more) and voriconazole is contraindicated due to a reduction in voriconazole plasma concentrations and possible loss of effect (see section 4.5).
Primjena ritonavira (400 mg dva puta na dan ili više) istodobno s vorikonazolom je kontraindicirana zbog smanjenja koncentracija vorikonazola u plazmi i mogućeg izostanka njegova djelovanja (vidjeti dio 4.5).
Co-administration of ritonavir with these medicinal products is expected to substantially increase their concentrations and may result in associated adverse reactions such as hypotension and prolonged erection (see section 4.5).
Pri primjeni ritonavira istodobno s tim lijekovima očekuje se značajan porast njihovih koncentracija što za posljedicu može imati nuspojave poput hipotenzije i produžene erekcije (vidjeti dio 4.5).
A higher frequency of adverse reactions (e.g., dizziness, nausea, paraesthesia) and laboratory abnormalities (elevated liver enzymes) have been observed when efavirenz is co-administered with ritonavir dosed as an antiretroviral agent.
Zamijećena je veća učestalost nuspojava (npr. omaglica, mučnina, parestezija) i laboratoriskih poremećaja (porast vrijednosti jetrenih enzima) kada se efavirenz davao istodobno s ritonavirom kao antiretrovirusnim lijekom.
There is no parenteral formulation of ritonavir, therefore the extent of absorption and absolute bioavailability have not been determined.
Budući da nema ritonavira za parenteralnu primjenu, stupanj apsorpcije ni apsolutna bioraspoloživost nisu određeni.
20, single dose 200q12h ↑ 124% ↔ The concomitant use of tadalafil for the treatment of erectile dysfunction with ritonavir dosed as an antiretroviral agent or as a pharmacokinetic enhancer should be with caution at reduced doses of no more than 10 mg tadalafil every 72 hours with increased monitoring for adverse reactions (see section 4.4).
20, jednokratna doza 200 svakih 12 h ↑ 124% ↔ Tadalafil za liječenje erektilne disfunkcije istodobno s ritonavirom kao antiretrovirusnim lijekom ili kao farmakokinetičkim pojačivačem treba davati oprezno, u manjim dozama, ne većima od 10 mg tadalafila svaka 72 sata i uz pažljivije praćenje mogućih nuspojava (vidjeti dio 4.4).
QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains 100 mg of ritonavir.
KVALITATIVNI I KVANTITATIVNI SASTAV Jedna filmom obložena tableta sadrži 100 mg ritonavira.
300 q12 h, 3 days
300 svakih 12 h, 3 dana
Due to the risk of bedaquiline related adverse events, co-administration should be avoided.
Zbog povećanog rizika od nuspojava uzrokovanih bedakilinom, istodobna primjena se mora izbjegavati.
QTcF interval was evaluated in a randomised, placebo and active (moxifloxacin 400 mg once daily) controlled crossover study in 45 healthy adults, with 10 measurements over 12 hours on Day 3.
U randomiziranom, placebom i aktivno (moksifloksacin 400 mg jedanput na dan) nadziranom, ukriženom ispitivanju u 45 zdravih odraslih osoba, s 10 mjerenja tijekom 12 sati trećeg dana ispitivanja evaluiran je QTcF interval.
• upset stomach or indigestion
• nadražen želudac ili probavne tegobe
Increased plasma concentrations of lovastatin and simvastatin; thereby, increasing the risk of myopathy including rhabdomyolysis (see section 4.5).
Povećane koncentracije lovastatina i simvastatina u plazmi; time se povećava rizik od miopatije, uključujući rabdomiolizu (vidjeti dio 4.5).
0.4 single oral dose
0,4 jednokratne oralne doze
3 Based on cross-study comparison to 800 mg indinavir three times daily alone.
3 Zasniva se na usporedbi među ispitivanjima s 800 mg indinavira triput na dan,
No interaction study is available with ritonavir only.
Ne postoje ispitivanja interakcija samo s ritonavirom.
It is not recommended to use ritonavir in patients receiving rivaroxaban, due to the risk of increased bleeding (see section 4.5).
Ne preporučuje se primjena ritonavira kod bolesnika koji uzimaju rivaroksaban zbog rizika od pojačanog krvarenja (vidjeti dio 4.5).
Co-administration of saquinavir and ritonavir has led to severe adverse reactions, mainly diabetic ketoacidosis and liver disorders, especially in patients with pre-existing liver disease.
Pri primjeni ritonavira istodobno sa sakvinavirom javile su se teške nuspojave, poglavito dijabetička ketoacidoza i poremećaji jetre, osobito u bolesnika s već prisutnom bolešću jetre.
HMG-CoA reductase inhibitor is indicated, pravastatin or fluvastatin is recommended.
Ako je indicirano liječenje inhibitorom HMGCoA reduktaze, preporučuje se pravastatin ili fluvastatin.
Decreased white blood cells, decreased haemoglobin, decreased neutrophils, increased eosinophils, thrombocytopenia
Smanjeni broj leukocita, snižena vrijednost hemoglobina, smanjeni broj neutrofila, povećani broj eozinofila, trombocitopenija
For further dosage recommendations, refer to the product information of other Protease Inhibitors approved for co-administration with ritonavir.
Za ostale preporuke o doziranju pročitati uputu o lijeku za druge inhibitore proteaza, odobrene za primjenu u kombinaciji s ritonavirom.
Anticoagulants Rivaroxaban
Antikoagulansi Rivaroksaban
Rifampicin and saquinavir (used for tuberculosis and HIV, respectively) as serious liver damage can occur when taken with ritonavir.
- Rifampicin i sakvinavir (prvi se daje za tuberkulozu, drugi za HIV), jer može nastupiti ozbiljno oštećenje jetre kada se ti lijekovi uzimaju s ritonavirom.
Feeling sick (nausea), vomiting or have stomach pain, because these may be signs of inflammation of the pancreas (pancreatitis).
- Mučnina, povraćanje ili bol u želucu, jer to mogu biti znakovi upale gušterače (pankreatitis).
Higher doses of ritonavir have been shown to be associated with an increased incidence of adverse reactions.
Pokazalo se da su veće doze povezane s povećanom učestalošću nuspojava.
Therefore, combination of bedaquiline with ritonavir should be avoided.
Stoga se mora izbjegavati kombinacija bedakilina i ritonavira.
Elderly Pharmacokinetic data indicated that no dose adjustment is necessary for elderly patients (see section
Stariji bolesnici Farmakokinetički podaci pokazuju da ne treba prilagođavati dozu u starijih bolesnika (vidjeti dio 5.2).
INFORMATION IN BRAILLE Ritonavir Mylan
16. PODACI NA BRAILLEOVOM PISMU Ritonavir Mylan
Increased digoxin levels observed in patients receiving ritonavir may lessen over time as induction develops (see section 4.4).
Povišene razine digoksina uočene u bolesnika koji primaju ritonavir mogu se s vremenom, s razvojem indukcije, sniziti (vidjeti dio 4.4).
Serum concentrations may be increased due to Breast Cancer Resistance Protein (BCRP) and acute P-gp inhibition by ritonavir.
Serumske se koncentracije mogu povećati zbog inhibicije proteina rezistencije raka dojke (engl. breast cancer resistant protein, BCRP) i akutne inhibicije P-gp-a uslijed djelovanja ritonavira.
Darunavir must be given with ritonavir to ensure its therapeutic effect.
Darunavir se mora davati s ritonavirom da bi se osigurao terapijski učinak.
Serum concentrations may be increased due to CYP3A inhibition by ritonavir, resulting in increased risk of tumour lysis syndrome at the dose initiation and during the ramp-up phase (see section 4.3 and refer to the venetoclax SmPC).
Serumske se koncentracije mogu povećati zbog inhibicijskog učinka ritonavira na CYP3A, što može povećati rizik od sindroma tumorske lize pri uvođenju liječenja i tijekom razdoblja povećavanja doze (vidjeti dio 4.3 i Sažetak opisa svojstava lijeka za venetoklaks).
The following adverse reactions of moderate to severe intensity with possible or probable relationship to ritonavir have been reported.
Niže su navedene prijavljene nuspojave umjerene do velike jačine, koje su moguće ili vjerojatno bile povezane s ritonavirom.
Data from concomitant use of parenteral midazolam with other protease inhibitors suggest a possible 3 - 4 fold increase in midazolam plasma levels.
Podaci o istodobnoj primjeri parenteralnog midazolama s drugim inhibitorima proteaza upućuju na to da se razine midazolama u plazmi mogu povećati 34 puta.
Each film-coated tablet contains 100 mg ritonavir.
Jedna filmom obložena tableta sadrži 100 mg ritonavira.
Serum concentrations of ibrutinib may be increased due to CYP3A inhibition by ritonavir, resulting in increased risk for toxicity including risk of tumor lysis syndrome.
Serumske se koncentracije ibrutiniba mogu povećati zbog inhibicijskog učinka ritonavira na CYP3A4, što može povećati rizik od toksičnosti uključujući rizik od sindroma tumorske lize.
Ritonavir pharmacokinetic parameters were not statistically significantly associated with body weight or lean body mass. Ritonavir plasma exposures in patients 50 - 70 years of age when dosed 100 mg in combination with lopinavir or at higher doses in the absence of other protease inhibitors is similar to that observed in younger adults.
Izloženost ritonaviru iz plazme u bolesnika 50 - 70 godina starosti, pri primjeni 100 mg ritonavira u kombinaciji s lopinavirom, ili u većim dozama ali bez drugog inhibitora proteaza, slična je onoj u mlađih bolesnika.
In a study completed in 2003, 50 HIV-1 infected, protease inhibitor and lamivudine naïve children age 4 weeks to 2 years received ritonavir 350 or 450 mg/m every 12 hours co-administered with zidovudine 160 mg/m every 8 hours and lamivudine 4 mg/kg every 12 hours.
U ispitivanju dovršenom 2003. godine, 50 djece u dobi od 4 tjedna do 2 godine, zaražene virusom HIV-1, koja prethodno nisu primala ni inhibitor proteaza ni lamivudin, dobivala su ritonavir 350 ili 450 mg/m² svakih 12 sati istodobno sa zidovudinom 160 mg/m² svakih 8 sati i lamivudinom 4 mg/kg svakih 12 sati.
Concomitant use of ritonavir (500 mg twice daily) dosed as an antiretroviral agent and rifabutin due to an increase of rifabutin serum concentrations and risk of adverse reactions including uveitis (see section
Pri istodobnoj primjeni ritonavira (500 mg dva puta na dan) doziranog kao antiretrovirusnog lijeka i rifabutina povećavaju se serumske koncentracije rifabutina, a time i rizik od nuspojava, uključujući uveitis (vidjeti dio 4.4).
The isopropylthiazole oxidation metabolite (M-2) is the major metabolite and has antiviral activity similar to that of parent compound.
Glavni je metabolit onaj koji nastaje oksidacijom izopropiltiazola (M-2), s protuvirusnom aktivnošću sličnom onoj matične tvari.
Dysgeusia, oral and peripheral paraesthesia, headache, dizziness, peripheral neuropathy
Vrlo često Disgeuzija, cirkumoralna i periferna parestezija, omaglica, periferna neuropatija
If you forget to take Ritonavir Mylan
Ako ste zaboravili uzeti Ritonavir Mylan
Trazodone is a CYP3A4 substrate and co-administration of ritonavir is expected to increase trazodone levels.
Trazodon je supstrat CYP3A4 i očekuje se da će istodobna primjena ritonavira povisiti razine trazodona.
However, if the benefit outweighs the risk, co-administration of bedaquiline with ritonavir must be done with caution.
Međutim, ukoliko korist nadmašuje rizik, prilikom istodobne primjene bedakilina s ritonavirom potreban je oprez.
Co-administration of ibrutinib and ritonavir should be avoided.
Potrebno je izbjegavati istodobnu primjenu ibrutinibia i ritonavira.
Tipranavir with ritonavir should not be used in treatment-naïve patients.
Tipranavir s ritonavirom se ne bi smio primjenjivati kod bolesnika koji nisu prethodno liječeni.
Concurrent administration of bupropion with repeated doses of ritonavir is expected to decrease bupropion levels.
Pri istodobnoj primjeni bupropiona s višekratnim dozama ritonavira očekuje se smanjenje razina bupropiona.
For some products, contraindications may be more relevant when ritonavir is used as an antiretroviral agent than when ritonavir is used as a pharmacokinetic enhancer (e.g. rifabutin and voriconazole):
Kontraindikacije za primjenu nekih lijekova mogu biti jače ako se ritonavir daje kao antiretrovirusni lijek nego ako se daje kao farmakokinetički pojačivač (npr. s rifabutinom ili s vorikonazolom):
600 q12 h Nevirapine Ritonavir Co-administration of ritonavir with nevirapine does not lead to clinically relevant changes in the pharmacokinetics of either nevirapine or ritonavir.
Primjena ritonavira istodobno s nevirapinom ne uzrokuje klinički značajne promjene farmakokinetike ni nevirapina ni ritonavira.
The relatively high frequency of diarrhoea during treatment with ritonavir may compromise the absorption and efficacy (due to decreased compliance) of ritonavir or other concurrent medicinal products.
Razmjerno velika učestalost proljeva tijekom liječenja ritonavirom može smanjiti apsorpciju i djelotvornost ritonavira i drugih lijekova koji se istodobno daju (zbog slabije suradljivosti).
Package leaflet: Information for the user Ritonavir Mylan 100 mg film-coated tablets ritonavir
Uputa o lijeku: Informacije za korisnika Ritonavir Mylan 100 mg filmom obložene tablete ritonavir
In a study completed in 2000, 76 HIV-1 infected children aged 6 months to 12 years who were protease inhibitor naive and naive to lamivudine and/or stavudine received ritonavir 350 or 450 mg/m2 every 12 hours co-administered with lamivudine and stavudine.
U ispitivanju dovršenom 2000. godine, 76 djece u dobi od 6 mjeseci do 12 godina, zaražene virusom HIV-1, koja prethodno nisu primala ni inhibitor proteaza ni lamivudin ni stavudin, dobivalo je ritonavir 350 ili 450 mg/m² svakih 12 sati istodobno s lamivudinom i stavudinom.
Therefore, if co-administration of delamanid with ritonavir is considered necessary, very frequent ECG monitoring throughout the full delamanid treatment period is recommended (see section 4.5 and refer to the delamanid Summary of Product Characteristics).
Stoga, ukoliko je nužna istodobna primjena delamanida i ritonavira, preporučuje se vrlo učestalo praćenje EKG-a bolesnika tijekom cijelog razdoblja liječenja delamanidom (vidjeti dio 4.5 i Sažetak opisa svojstava lijeka za delamanid).
For more detailed dose recommendations, including those for children, see the Package Leaflet of the anti-HIV medicines Ritonavir Mylan is given in combination with.
Više potankosti o preporučenim dozama, uključujući doziranje u djece, naći ćete u uputi o lijeku za lijek u kombinaciji s kojim se Ritonavir Mylan daje.
↓ 25% ND
↓ 40% NO
Due to the large increase in rifabutin AUC, the concomitant use of rifabutin with ritonavir dosed as an antiretroviral agent is contraindicated (see section 4.3).
Zbog velikog porasta AUC rifabutina, primjena ritonavira kao antiretrovirusnog lijeka ili kao farmakokinetičkog pojačivača istodobno s rifabutinom je kontraindicirana (vidjeti dio 4.3).
20 mg, single dose
20 mg, jednokratna doza
The following warnings and precautions should be considered when ritonavir is used as an antiretroviral agent.
Niže navedena upozorenja i mjere opreza valja razmotriti kada se ritonavir daje kao antiretrovirusni lijek.
Concomitant use of neratinib with ritonavir is contraindicated due to serious and/or life threatening potential reactions including hepatotoxicity (see section 4.3).
Istodobna primjena neratiniba i ritonavira je kontraindicirana zbog ozbiljnih i/ili po život opasnih mogućih reakcija, uključujući hepatotoksičnost (vidjeti dio 4.3).
Patients with impaired renal function
Bolesnici s oštećenom funkcijom bubrega
Smoke cessation Buproprion
Sredstva za odvikavanje od pušenja Bupropion
PDE5 inhibitor
Inhibitor PDE5
Sleeping agent Zolpidem200, 4doses ↑ 28% ↑ 22% Zolpidem and ritonavir may be co-administered with careful monitoring for excessive sedative effects.
Sredstva za spavanje Zolpidem200, 4 doze Zolpidem i ritonavir mogu se davati istodobno, uz pažljivo praćenje radi sprečavanja eventualnih pretjeranih sedacijskih učinaka.
100, single oral dose
100, jednokratna oralna doza
Co-administration of ritonavir and medicinal products primarily metabolised by CYP3A may result in increased plasma concentrations of the other medicinal product, which could increase or prolong its therapeutic and adverse effects.
Pri istodobnoj primjeni ritonavira istodobno s lijekovima koji se prvenstveno metaboliziraju putem CYP3A mogu se povećati plazmatske koncentracije drugog lijeka i time povećati ili produžiti njegovi terapijski, ali i neželjeni učinci.
No human data on the effect of ritonavir on fertility are available.
Podaci o učinku ritonavira na plodnost u ljudi nisu dostupni.
Increased plasma concentrations of astemizole and terfenadine.
Povećane koncentracije astemizola i terfenadina u plazmi.
200 q12 h/1 h before
200 svakih 12 h/1 h prije
500 q12 h ↓ 62% ↓ 59%
500 svakih 12 h ↓ 62% ↓ 59%
The HMG-CoA reductase inhibitors simvastatin and lovastatin are highly dependent on CYP3A for metabolism, thus concomitant use of ritonavir with simvastatin or lovastatin is not recommended due to an increased risk of myopathy including rhabdomyolysis.
Metabolizam inhibitora HMG-CoA reduktaze simvastatina i lovastatina vrlo je ovisan o CYP3A te se stoga primjena ritonavira istodobno sa simvastatinom ili lovastatinom ne preporučuje zbog povećanog rizika od miopatije, uključujući rabdomiolizu.
When tadalafil is used concurrently with ritonavir in patients with pulmonary arterial hypertension, refer to the tadalafil Summary of Product Characteristics.
Kada se tadalafil primjenjue istodobno s ritonavirom kod bolesnika s plućnom arterijskom hipertenzijom, treba pogledati Sažetak opisa svojstava lijeka za tadalafil.
Rationale
Razlog
40 mg, single dose
40 mg, jednokratna doza
Ritonavir should be started at 250 mg/m and increased at 2 to 3 day intervals by 50 mg/m twice daily.
Liječenje treba početi dozom ritonavira od 250 mg/m² dvaput na dan i povećavati je u razmacima od 2 do 3 dana za po 50 mg/m².
Trazodone (a medicine for depression) as, unwanted effects like nausea, dizziness, low blood pressure and fainting can occur when taken with ritonavir.
- Trazodon (lijek za depresiju), jer se pri njegovu uzimanju s ritonavirom mogu javiti nuspojave poput mučnine, omaglice, niskog krvnog tlaka i nesvjestice.
Upon multiple dosing, ritonavir accumulation is slightly less than predicted from a single dose due to a time and dose-related increase in apparent clearance (Cl/F).
Nakupljanje ritonavira nakon višekratnog doziranja bilo je malo slabije nego što se predviđalo na temelju podataka dobivenih jednokratnim doziranjem, zbog prividnog klirensa (Cl/F) ovisnog o vremenu i o dozi.
• feeling weak/tired
• osjećaj slabosti/umora
Pethidine, piroxicam, propoxyphene
Petidin, piroksikam, propoksifen
Adult Use
Primjena u odraslih
Atazanavir 300 mg once daily with ritonavir 100 mg once daily.
Atazanavir 300 mg jedanput na dan s ritonavirom 100 mg jedanput na dan.
500 q12 h ↓ 40% ↓ 32%
500 svakih 12 h ↓ 40% ↓ 32%
The frequency of this is unknown (see section 4.4).
Učestalost te nuspojave nije poznata (vidjeti dio 4.4).
Ritonavir should not be given as a pharmacokinetic enhancer to patients with decompensated liver disease, (see section 4.3).
Ritonavir se ne smije davati kao farmakokinetički pojačivač bolesnicima s dekompenziranom bolešću jetre (vidjeti dio 4.3).
Ritonavir dosed as an antiretroviral agent is likely to inhibit CYP2D6 and as a result is expected to increase concentrations of imipramine, amitriptyline, nortriptyline, fluoxetine, paroxetine or sertraline.
Ritonavir doziran kao antiretrovirusni lijek vjerojatno inhibira CYP2D6 zbog čega se očekuje povećanje koncentracije imipramina, amitriptilina, nortriptilina, fluoksetina, paroksetina i sertralina.
Since the renal clearance of ritonavir is negligible, the decrease in the total body clearance is not expected in patients with renal impairment (see also section 4.2).
Budući da je klirens bubrega za ritonavir zanemarivo malen, ne očekuje se smanjenje ukupnog tjelesnog klirensa u bolesnika s oštećenjem funkcije bubrega (vidjeti i dio 4.2).
In addition to the opportunistic infections, autoimmune disorders (a condition that occurs when the immune system attacks healthy body tissue) may also occur after you start taking medicines for the treatment of your HIV infection.
Nakon što počnete primjenjivati lijekove za liječenje Vaše HIV-infekcije, uz oportunističke infekcije također se mogu javiti i autoimuni poremećaji (stanja u kojima imunološki sustav napada vlastito zdravo tkivo).
For additional information on the effect of ritonavir on co-administered protease inhibitor metabolism, see section 4.5 and refer to the Summary of Product Characteristics of the particular co-administered PIs.
Za dodatne informacije o utjecaju ritonavira na metabolizam istodobno primijenjenog inhibitora proteaza vidjeti dio 4.5 i pročitati Sažetak opisa svojstava lijeka za odgovarajući istodobno primijenjeni IP.
Fosamprenavir must be given with ritonavir to ensure its therapeutic effect.
Fosamprenavir se mora davati s ritonavirom da bi se osigurao terapijski učinak.
While rosuvastatin elimination is not dependent on CYP3A, an elevation of rosuvastatin exposure has been reported with ritonavir co-administration.
Iako eliminacija rosuvastatina ne ovisi o CYP3A, prijavljena je povećana izloženost rosuvastatinu pri njegovoj istodobnoj primjeni s ritonavirom.
Concomitant use of sildenafil with ritonavir is contraindicated in pulmonary arterial hypertension patients (see section 4.3).
Istodobna primjena sildenafila s ritonavirom je kontraindicirana u bolesnika s plućnom arterijskom hipertenzijom (vidjeti dio 4.3).
The metabolism of pravastatin and fluvastatin is not dependent on CYP3A, and interactions are not expected with ritonavir.
Metabolizam pravastatina ni fluvastatina ne ovisi o CYP3A, te se ne očekuje njihova interakcija s ritonavirom.
if you are currently taking any of the following medicines: astemizole or terfenadine (commonly used to treat allergy symptoms - these medicines may be available without prescription); amiodarone, bepridil, dronedarone, encainide, flecainide, propafenone, quinidine (used to correct irregular heartbeats); dihydroergotamine, ergotamine (used to treat migraine headache); ergonovine, methylergonovine (used to stop excessive bleeding that may occur following childbirth or an abortion); clorazepate, diazepam, estazolam, flurazepam, triazolam or oral (taken by mouth) midazolam (used to help you sleep and/or relieve anxiety); clozapine, pimozide, (used to treat abnormal thoughts or feelings); quetiapine (used to treat schizophrenia, bipolar disorder and major depressive disorder); lurasidone (used to treat depression); ranolazine (used to treat chronic chest pain [angina]); pethidine, piroxicam, propoxyphene (used to relieve pain); cisapride (used to relieve certain stomach problems);
- ako trenutno uzimate bilo koji od ovih lijekova: - astemizol ili terfenadin (obično se koriste za liječenje simptoma alergije - ti se lijekovi možda mogu nabaviti i bez liječničkog recepta); - amiodaron, bepridil, dronedaron, enkainid, flekainid, propafenon, kinidin (koriste se za regulaciju nepravilnih otkucaja srca); - dihidroergotamin, ergotamin (koriste se za liječenje migrenske glavobolje); - ergonovin, metilergonovin (koriste se za zaustavljanje pretjeranog krvarenja koje može nastupiti nakon porođaja ili pobačaja); - klorazepat, diazepam, estazolam, flurazepam, triazolam ili oralni (uzet kroz usta) midazolam (koristi se za spavanje i/ili ublažavanje tjeskobe); - klozapin, pimozid (koriste se za liječenje nenormalnih misli ili osjećaja); - kvetiapin (koristi se za liječenje shizofrenije, bipolarnog poremećaja i velikog depresivnog poremećaja; - lurasidon (lijek za liječenje depresije);